882 related articles for article (PubMed ID: 30888999)
1. Comparing the Staging/Restaging Performance of 68Ga-Labeled Prostate-Specific Membrane Antigen and 18F-Choline PET/CT in Prostate Cancer: A Systematic Review and Meta-analysis.
Lin CY; Lee MT; Lin CL; Kao CH
Clin Nucl Med; 2019 May; 44(5):365-376. PubMed ID: 30888999
[TBL] [Abstract][Full Text] [Related]
2. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
3.
von Eyben FE; Picchio M; von Eyben R; Rhee H; Bauman G
Eur Urol Focus; 2018 Sep; 4(5):686-693. PubMed ID: 28753806
[TBL] [Abstract][Full Text] [Related]
4. 18 F-prostate specific membrane antigen positron emission tomography/computerized tomography for lymph node staging in medium/high risk prostate cancer: A systematic review and meta-analysis.
Lv Z; Song L; Wang M; Hou H; Li H; Wang X; Wang J; Wang J; Liu M
Chin Med J (Engl); 2024 Apr; 137(8):949-958. PubMed ID: 37690993
[TBL] [Abstract][Full Text] [Related]
5. Diagnostic Accuracy of
Satapathy S; Singh H; Kumar R; Mittal BR
AJR Am J Roentgenol; 2021 Mar; 216(3):599-607. PubMed ID: 32755196
[No Abstract] [Full Text] [Related]
6. Head-to-Head Comparison of
Kuten J; Fahoum I; Savin Z; Shamni O; Gitstein G; Hershkovitz D; Mabjeesh NJ; Yossepowitch O; Mishani E; Even-Sapir E
J Nucl Med; 2020 Apr; 61(4):527-532. PubMed ID: 31562225
[No Abstract] [Full Text] [Related]
7. Comparison of
Schwenck J; Rempp H; Reischl G; Kruck S; Stenzl A; Nikolaou K; Pfannenberg C; la Fougère C
Eur J Nucl Med Mol Imaging; 2017 Jan; 44(1):92-101. PubMed ID: 27557844
[TBL] [Abstract][Full Text] [Related]
8. New Clinical Indications for (18)F/(11)C-choline, New Tracers for Positron Emission Tomography and a Promising Hybrid Device for Prostate Cancer Staging: A Systematic Review of the Literature.
Evangelista L; Briganti A; Fanti S; Joniau S; Reske S; Schiavina R; Stief C; Thalmann GN; Picchio M
Eur Urol; 2016 Jul; 70(1):161-175. PubMed ID: 26850970
[TBL] [Abstract][Full Text] [Related]
9. The meta-analysis of the effect of 68Ga-PSMA-PET/CT diagnosis of prostatic cancer compared with bone scan.
Zhao R; Li Y; Nie L; Qin K; Zhang H; Shi H
Medicine (Baltimore); 2021 Apr; 100(15):e25417. PubMed ID: 33847640
[TBL] [Abstract][Full Text] [Related]
10. Gallium-68 Prostate-specific Membrane Antigen Positron Emission Tomography in Advanced Prostate Cancer-Updated Diagnostic Utility, Sensitivity, Specificity, and Distribution of Prostate-specific Membrane Antigen-avid Lesions: A Systematic Review and Meta-analysis.
Perera M; Papa N; Roberts M; Williams M; Udovicich C; Vela I; Christidis D; Bolton D; Hofman MS; Lawrentschuk N; Murphy DG
Eur Urol; 2020 Apr; 77(4):403-417. PubMed ID: 30773328
[TBL] [Abstract][Full Text] [Related]
11. Sensitivity, Specificity, and Predictors of Positive
Perera M; Papa N; Christidis D; Wetherell D; Hofman MS; Murphy DG; Bolton D; Lawrentschuk N
Eur Urol; 2016 Dec; 70(6):926-937. PubMed ID: 27363387
[TBL] [Abstract][Full Text] [Related]
12.
Corfield J; Perera M; Bolton D; Lawrentschuk N
World J Urol; 2018 Apr; 36(4):519-527. PubMed ID: 29344682
[TBL] [Abstract][Full Text] [Related]
13. Comparison of PSMA-PET/CT, choline-PET/CT, NaF-PET/CT, MRI, and bone scintigraphy in the diagnosis of bone metastases in patients with prostate cancer: a systematic review and meta-analysis.
Zhou J; Gou Z; Wu R; Yuan Y; Yu G; Zhao Y
Skeletal Radiol; 2019 Dec; 48(12):1915-1924. PubMed ID: 31127357
[TBL] [Abstract][Full Text] [Related]
14.
Caroli P; Sandler I; Matteucci F; De Giorgi U; Uccelli L; Celli M; Foca F; Barone D; Romeo A; Sarnelli A; Paganelli G
Eur J Nucl Med Mol Imaging; 2018 Nov; 45(12):2035-2044. PubMed ID: 29922948
[TBL] [Abstract][Full Text] [Related]
15. Detection of recurrent prostate cancer lesions before salvage lymphadenectomy is more accurate with (68)Ga-PSMA-HBED-CC than with (18)F-Fluoroethylcholine PET/CT.
Pfister D; Porres D; Heidenreich A; Heidegger I; Knuechel R; Steib F; Behrendt FF; Verburg FA
Eur J Nucl Med Mol Imaging; 2016 Jul; 43(8):1410-7. PubMed ID: 26993315
[TBL] [Abstract][Full Text] [Related]
16. PET/CT With
Giovacchini G; Giovannini E; Riondato M; Ciarmiello A
Curr Radiopharm; 2018; 11(1):4-13. PubMed ID: 29090673
[TBL] [Abstract][Full Text] [Related]
17. Staging/restaging performance of F18-fluorodeoxyglucose positron emission tomography/magnetic resonance imaging in breast cancer: A review and meta-analysis.
Lin CY; Lin CL; Kao CH
Eur J Radiol; 2018 Oct; 107():158-165. PubMed ID: 30292261
[TBL] [Abstract][Full Text] [Related]
18. 68Ga-PSMA-11 PET-CT study in prostate cancer patients with biochemical recurrence and non-contributive 18F-Choline PET-CT: Impact on therapeutic decision-making and biomarker changes.
Barbaud M; Frindel M; Ferrer L; Le Thiec M; Rusu D; Rauscher A; Maucherat B; Baumgartner P; Fleury V; Colombié M; Thierry-Morel A; Kraeber-Bodéré F; Campion L; Rousseau C
Prostate; 2019 Apr; 79(5):454-461. PubMed ID: 30549066
[TBL] [Abstract][Full Text] [Related]
19. In primary lymph nodal staging of patients with high-risk and intermediate-risk prostate cancer, how critical is the role of Gallium-68 prostate-specific membrane antigen positron emission tomography-computed tomography?
Kulkarni SC; Sundaram PS; Padma S
Nucl Med Commun; 2020 Feb; 41(2):139-146. PubMed ID: 31714366
[TBL] [Abstract][Full Text] [Related]
20. Detection Rate of
Jilg CA; Drendel V; Rischke HC; Beck TI; Reichel K; Krönig M; Wetterauer U; Schultze-Seemann W; Meyer PT; Vach W
J Nucl Med; 2019 Jul; 60(7):971-977. PubMed ID: 30683768
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]